Hepatic apolipoprotein B (apoB)-containing lipoproteins are the predominant carriers of plasma cholesterol and, in elevated concentrations, represent a positive risk factor for the development of premature coronary artery atherosclerosis. Despite its importance of numerous aspects of lipoprotein metabolism, including the prevention and treatment of hyperlipidemias and their complications, the mechanism underlying the hepatic assembly of apoB-containing lipoprotein remains poorly defined. The overall goal of the proposed research is to characterized apoB's interactions with lipids, membranes and the microsomal triglyceride transfer protein (MTP) and to understand how these interactions results in the assembly and regulation of apoB-containing lipoproteins. The following specific aims will be addressed: I. Define how the amino-terminal domain of apoB functions to initiate lipoprotein formation in the hepatic endoplasmic reticulum (ER). To define how this domain functions, its properties will be analyzed using several in vitro assays designed to reflect potential functions during lipoprotein assembly in vivo. For each assay the behavior of native and chemically reduced apoB17 (amino-terminal 17% of apoB) was well as apoB17 harboring specific cysteine to serine mutations will be studied. The critical function of this domain will emerge by identifying which assay(s) displays a structure-function profile similar to that observed for apoB17's capacity to initiate lipoprotein assembly in vivo; II. Establish whether the initial co-translational phase of lipoprotein assembly requires recruitment by apoB of specific lipid classes. This question will be addressed by determining the relative lipid compositions of a series of C- terminally truncated, epitope-tagged forms of apoB that are though to represent static intermediates in the normal process of co-translational lipoprotein formation; III. Identify and characterize intermediates in the post-translational folding and assembly of apoB28. Since the post- translational assembly of apoB28 can be readily synchronized and manipulated, intermediates in this process can be identified as can the roles of cellular factors with known or proposed roles in the process of lipoprotein assembly; IV. Unequivocally establish the topology of apoB within the hepatic ER. The prevailing, through controversial view of the regulation of apoB secretion, involves the capacity of the hepatocyte to regulate the translocation of apoB across the R membrane in response to lipid availability. To establish unequivocally whether cytosolic, translocation arrested forms of apoB exist within the hepatic ER, the extent of glycosylation at specific sites within the C-terminal 50% of the protein will be monitored.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL049373-07
Application #
6110210
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
041418799
City
Winston-Salem
State
NC
Country
United States
Zip Code
27106
Schugar, Rebecca C; Shih, Diana M; Warrier, Manya et al. (2017) The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue. Cell Rep 19:2451-2461
Pollard, Ricquita D; Fulp, Brian; Sorci-Thomas, Mary G et al. (2016) High-Density Lipoprotein Biogenesis: Defining the Domains Involved in Human Apolipoprotein A-I Lipidation. Biochemistry 55:4971-81
Rodríguez-Pérez, Celia; Ramprasath, Vanu Ramkumar; Pu, Shuaihua et al. (2016) Docosahexaenoic Acid Attenuates Cardiovascular Risk Factors via a Decline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Plasma Levels. Lipids 51:75-83
Warrier, Manya; Zhang, Jun; Bura, Kanwardeep et al. (2016) Sterol O-Acyltransferase 2-Driven Cholesterol Esterification Opposes Liver X Receptor-Stimulated Fecal Neutral Sterol Loss. Lipids 51:151-7
Ohshiro, Taichi; Ohtawa, Masaki; Nagamitsu, Tohru et al. (2015) New pyripyropene A derivatives, highly SOAT2-selective inhibitors, improve hypercholesterolemia and atherosclerosis in atherogenic mouse models. J Pharmacol Exp Ther 355:299-307
Jones, Peter J H; MacKay, Dylan S; Senanayake, Vijitha K et al. (2015) High-oleic canola oil consumption enriches LDL particle cholesteryl oleate content and reduces LDL proteoglycan binding in humans. Atherosclerosis 238:231-8
Lopez, Adam M; Chuang, Jen-Chieh; Posey, Kenneth S et al. (2015) PRD125, a potent and selective inhibitor of sterol O-acyltransferase 2 markedly reduces hepatic cholesteryl ester accumulation and improves liver function in lysosomal acid lipase-deficient mice. J Pharmacol Exp Ther 355:159-67
Liu, Mingxia; Allegood, Jeremy; Zhu, Xuewei et al. (2015) Uncleaved ApoM signal peptide is required for formation of large ApoM/sphingosine 1-phosphate (S1P)-enriched HDL particles. J Biol Chem 290:7861-70
Melchior, John T; Olson, John D; Kelley, Kathryn L et al. (2015) Targeted Knockdown of Hepatic SOAT2 With Antisense Oligonucleotides Stabilizes Atherosclerotic Plaque in ApoB100-only LDLr-/- Mice. Arterioscler Thromb Vasc Biol 35:1920-7
Marshall, Stephanie M; Gromovsky, Anthony D; Kelley, Kathryn L et al. (2014) Acute sterol o-acyltransferase 2 (SOAT2) knockdown rapidly mobilizes hepatic cholesterol for fecal excretion. PLoS One 9:e98953

Showing the most recent 10 out of 242 publications